Who are ICS/LABA and Montelukast's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ics-laba-and-montelukast.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ICS/LABA and Montelukast — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ICS/LABA and Montelukast (ICS/LABA and Montelukast) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ICS/LABA combination with leukotriene receptor antagonist. Area: Respiratory/Pulmonology.

marketed ICS/LABA combination with leukotriene receptor antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, cysteinyl leukotriene receptor (CysLT1) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

ICS/LABA and Montelukast (ICS/LABA and Montelukast) — The First Affiliated Hospital of Guangzhou Medical University. This combination reduces airway inflammation and bronchoconstriction by suppressing inflammatory mediators and relaxing airway smooth muscle.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ICS/LABA and Montelukast TARGET	ICS/LABA and Montelukast	The First Affiliated Hospital of Guangzhou Medical University	marketed	ICS/LABA combination with leukotriene receptor antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, cysteinyl leukotriene receptor (CysLT1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ICS/LABA combination with leukotriene receptor antagonist class)

The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ICS/LABA and Montelukast — Competitive Intelligence Brief. https://druglandscape.com/ci/ics-laba-and-montelukast. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab